You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF V600

Showing 1 - 25 of 3,787
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Associated Factors, and Clinical Outcomes of Prescribing

Completed
  • BRAF v600 Mutated Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Pharmaceuticals
    Mar 28, 2023

    Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

    Not yet recruiting
    • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
    • Non-investigational
    • (no location specified)
    May 11, 2023

    Cancer Trial (Dabrafenib, Trametinib)

    Not yet recruiting
    • Cancer
    • (no location specified)
    May 25, 2023

    Non Small Cell Lung Cancer Trial (HLX208+HLX10)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • HLX208+HLX10
    • (no location specified)
    Nov 30, 2022

    Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

    Not yet recruiting
    • Colorectal Cancer
    • +4 more
    • (no location specified)
    Aug 18, 2022

    Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy

    Not yet recruiting
    • Colorectal Cancer Metastatic
    • Tunlametinib plus Vemurafenib
    • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
    • (no location specified)
    Aug 15, 2023

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • BRAF V600E Mutation Positive
    • Encorafenib Oral Capsule + Cetuximab
    • (no location specified)
    Jan 30, 2023

    BRAF V600-mutated Lung Carcinoma Treated With Combination of

    Completed
    • Non Small Cell Lung Cancer
    • BRAF V600 Mutation
      • Créteil, France
      • +1 more
      Jun 29, 2022

      Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

      Not yet recruiting
      • Cancer
      • +5 more
      • (no location specified)
      Aug 18, 2022

      BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

      Recruiting
      • Metastatic Non-small Cell Lung Cancer
      • BRAF V600 Mutation
        • Lyon, Rhône Alpes, France
          CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
        Sep 14, 2022

        BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

        Completed
        • BRAF V600E Unresectable or Metastatic Melanoma
        • +2 more
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Center
        Jun 9, 2022

        Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

        Not yet recruiting
        • Non-small-cell Lung Cancer
        • (no location specified)
        Jun 8, 2023

        BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

        Recruiting
        • BRAF NP_004324.2:p.V600M
        • +6 more
        • Portland, Oregon
          Providence Portland Medical Center
        Aug 17, 2022

        Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

        Recruiting
        • Clinical Stage IV Cutaneous Melanoma AJCC v8
        • +3 more
        • Scottsdale, Arizona
        • +2 more
        Jan 4, 2023

        Primary Malignant Brain Tumor Trial in China (ABM-1310)

        Not yet recruiting
        • Primary Malignant Brain Tumor
        • Beijing, Beijing, China
        • +3 more
        May 28, 2023

        Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)

        Recruiting
        • Colorectal Cancer
        • VIC
        • Bevacizumab Plus Chemotherapy
        • Shanghai, China
          Department of General Surgery, Zhongshan Hospital, Fudan Univers
        Sep 14, 2022

        Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

        Not yet recruiting
        • Advanced Solid Tumor
        • BRAF V600 Mutation
        • Nanchang, Jiangxi, China
        • +2 more
        Aug 12, 2022

        Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)

        Recruiting
        • Metastatic Colorectal Cancer
        • mCRC
        • Shenyang, Liaoning, China
          Liaoning Cancer Hospital
        May 1, 2022

        NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • +32 more
        • (no location specified)
        Mar 30, 2023

        CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

        Recruiting
        • CRC
        • HLX208
        • Cetuximab Injection [Erbitux]
        • Shanghai, China
          Fudan University Affiliated Oncology Hospital
        Dec 30, 2021

        BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

        Active, not recruiting
        • BRAF NP_004324.2:p.V600X
        • +6 more
        • Cetuximab
        • +4 more
        • Houston, Texas
          M D Anderson Cancer Center
        Sep 22, 2022

        BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

        Recruiting
        • BRAF NP_004324.2:p.V600E
        • +2 more
        • Duarte, California
        • +1 more
        Jan 19, 2023

        Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

        Recruiting
        • Anaplastic Thyroid Cancer
        • ATC
        • Shanghai, China
          Fudan University Affiliated Oncology Hospital
        Dec 30, 2021